Glembatumumab vedotin: Phase I/II started

Celldex began an open-label, U.S. Phase I/II trial of IV glembatumumab vedotin given every 3 weeks in about 49 patients who have progressed on prior platinum-based chemotherapy. The dose-escalation Ph...